Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Bietti crystalline corneoretinal dystrophy: Advances in understanding and gene therapeutic approaches.

Molecular vision - 1 Jan 2025

Zhao Guangrong, Ding Dayou

Abstract excerpt

Bietti crystalline dystrophy (BCD), an autosomal recessive inherited retinal disorder caused by mutations in the CYP4V2 gene, has long remained therapeutically challenging. Recent advances in adeno-associated virus-based gene therapy have emerged as promising therapeutic strategies for patients with BCD. This review synthesizes current knowledge regarding the molecular genetic mechanisms underlying BCD...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Corneal Dystrophies, Hereditary
Share to Cytochrome P-450 Enzyme System
Share to Cytochrome P450 Family 4

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Dependovirus

Share to Genetic Therapy

Share to Mutation

Share to Retinal Diseases

Source

Open in PubMed Open full text

Identifiers

PMID: 41306488
PMCID: PMC12645063

Genes

CYP4V2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Bietti crystalline corneoretinal dystrophy: Advances in understanding and gene therapeutic approaches.PMID 41306488Read ↗

Gene replacement therapy in Bietti crystalline corneoretinal dystrophy: an open-label, single-arm, exploratory trialSemantic proximity Read ↗

AAV2-mediated gene therapy for Bietti crystalline dystrophy provides functional CYP4V2 in multiple relevant cell models.Semantic proximity Read ↗

In vivo genome editing via CRISPR/Cas9-mediated homology-independent targeted integration for Bietti crystalline corneoretinal dystrophy treatment.Semantic proximity Read ↗

Emerging Gene Manipulation Strategies for the Treatment of Monogenic Eye Disease.Semantic proximity Read ↗

Gene therapy for inherited retinal diseases: progress and possibilitiesSemantic proximity Read ↗

A novel and efficient murine model of Bietti crystalline dystrophy.Semantic proximity Read ↗

AAV-mediated gene-replacement therapy restores viability of BCD patient iPSC derived RPE cells and vision of Cyp4v3 knockout mice.Semantic proximity Read ↗

Unravelling CYP4V2: Clinical features, genetic insights, pathogenic mechanisms and therapeutic strategies in Bietti crystalline corneoretinal dystrophySemantic proximity Read ↗

Gene Therapy for Non-Hereditary Retinal Disease: Age-Related Macular Degeneration, Diabetic Retinopathy, and BeyondSemantic proximity Read ↗

Gene therapy strategies in ophthalmology—an overview of current developments and future prospectsSemantic proximity Read ↗

Gene therapy and the adeno‐associated virus in the treatment of genetic and acquired ophthalmic diseases in humans: Trials, future directions and safety considerationsSemantic proximity Read ↗

Gene therapy for choroideremia: progress, potential and pitfallsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.